Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

3.80
-0.3100-7.54%
Post-market: 3.800.00000.00%19:30 EDT
Volume:908.74K
Turnover:3.57M
Market Cap:316.14M
PE:-2.94
High:4.21
Open:4.17
Low:3.77
Close:4.11
52wk High:5.81
52wk Low:1.17
Shares:83.20M
Float Shares:65.21M
Volume Ratio:0.82
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2925
EPS(LYR):-0.8000
ROE:-4796.52%
ROA:-48.06%
PB:-24.34
PE(LYR):-4.75

Loading ...

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

THOMSON REUTERS
·
Aug 20

Longeveron - Marie Washburn Steps Down as CFO, Returns to Corporate Controller Role

THOMSON REUTERS
·
Aug 20

Opus Genetics Grants Options for 310,000 Shares Under Inducement Plan

Reuters
·
Aug 20

Opus Genetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 20

Opus Genetics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Opus Genetics (IRD) Receives a Buy from Piper Sandler

TIPRANKS
·
Aug 07

Cantor Fitzgerald Sticks to Their Buy Rating for Opus Genetics (IRD)

TIPRANKS
·
Aug 07

RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 07

Opus Genetics Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Opus Genetics - May Offer and Sell up to $300 Mln of Securities - SEC Filing

THOMSON REUTERS
·
Aug 07

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 07

Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate

Benzinga Earnings
·
Aug 06

Opus Genetics Q2 FY26 Net Loss Widens to $8.1 Million; Revenue Drops to $755,000

Reuters
·
Aug 06

Opus Genetics Inc Q2 Pretax Profit USD -8.098 Million

THOMSON REUTERS
·
Aug 06

Press Release: Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Dow Jones
·
Aug 06

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 04

Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder

MT Newswires Live
·
Aug 03

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of Opgx-Lca5 for Lca5-Associated Inherited Retinal Disease

THOMSON REUTERS
·
Aug 03

Opus Genetics - May Submit Bla Based on Six-Month Efficacy Data

THOMSON REUTERS
·
Aug 03

Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX) and Opus Genetics (IRD)

TIPRANKS
·
Jul 31